Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + mFOLFOX6
- Development stage
- Phase 2
- Lead developer
- Astellas Pharma
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Erlotinib + mFOLFOX6 is a combination regimen used in oncology clinical trials, primarily for the treatment of advanced or metastatic gastrointestinal cancers such as esophageal/gastroesophageal junction (Eso/GEJ) adenocarcinoma and metastatic colorectal cancer. Erlotinib is an oral small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which blocks EGFR signaling pathways involved in tumor cell proliferation and survival. mFOLFOX6 is a modified version of the FOLFOX chemotherapy regimen, consisting of oxaliplatin (a platinum-based DNA crosslinker), leucovorin (folinic acid, which enhances 5-fluorouracil activity), and 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase). The combination aims to leverage both targeted therapy against EGFR and cytotoxic chemotherapy to improve response rates in patients with certain gastrointestinal malignancies[1][2][7].
02
Targets
TS (Thymidylate synthase)Pt-DNA adduct (DNA-oxaliplatin adduct)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on erlotinib + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + mFOLFOX6.